skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

8 Total results for product and free and sample content found

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Induced Pluripotent Stem Cells Help Eisai's Hunt For Novel Parkinson's Leads

26 Oct 2018

Induced Pluripotent Stem Cells Help Eisai's Hunt For Novel Parkinson's Leads

As part of broader efforts to pursue novel approaches to common neurological disorders, Eisai uses iPSC-derived cells to help identify potential new drug therapies for Parkinson's.

Topic Parkinsons disease

Scrip: 世界の医療用医薬品&製薬産業に関するニュース, In Vivo: 医療用医薬...

What actually keeps biopharma execs up at night?

07 Sep 2017

What actually keeps biopharma execs up at night?

What actually keeps biopharma execs up at night? Take our quiz to find out. 

Topic deal-trends diseases drug-development-landscape fda medtech personalized-medicine parkinsons-disease reimbursement

Pharmaprojects: 医薬品開発パイプラインのデータベース

Emerging therapies in Parkinson’s Disease

24 Jul 2017

Emerging therapies in Parkinson’s Disease

Thirty-five drugs are presently available in multiple global markets for Parkinson’s disease (PD) patients.

Topic parkinsons-disease

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Prexton CEO on future for novel Parkinson's therapy

12 Apr 2017

As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's technology and its future.

Topic parkinsons-disease

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

After several setbacks, Xadago has received a less than ideal FDA approval in Parkinson’s disease

By Stephanie Yip 28 Mar 2017

On 21 March 2017, Newron Pharmaceuticals and its partners Zambon and US WorldMeds announced the approval of Xadago (safinamide) for the treatment of Parkinson’s disease (PD) as an add-on therapy to levodopa/carbidopa for patients experiencing “off” periods (BusinessWire, 2017; FDA press release, 2017). This approval was long-awaited by Newron and its US partner, US WorldMeds, as it followed numerous earlier US regulatory setbacks. Newron and its partner are now looking to successfully launch Xadago, but the US approved label fell short of ideal as it did not extend to early-stage PD patients receiving dopamine agonists  

Topic diseases parkinsons-disease

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Positive Phase III data for CVT-301

14 Feb 2017

Positive Phase III data for CVT-301 confirm its potential as a new rescue therapy for fluctuating Parkinson’s disease patients

Topic parkinsons-disease

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Ensure your Successful Entrance into the Parkinson’s Disease Market

03 Aug 2015

Entering a established market as a new player can be daunting. It's difficult to know exactly where you should be targeting your trial, and also who you should be targeting your treatment at.

Topic parkinsons-disease

Pharmaprojects: 医薬品開発パイプラインのデータベース

Raise Awareness for Parkinson's Drug Development on Moving Day

01 May 2014

A report that analyses the current clinical development landscape for Parkinson's Disease

Topic parkinsons-disease

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。